CDK4 and nasopharyngeal carcinoma: The Hsp90 inhibitor AT13387 could inhibit NPC C666-1 cell growth and induced cellular senescence with the downregulation of multiple Hsp90 client oncoproteins EGFR, AKT, CDK4, and significantly suppressed tumor formation in C666-1 NPC xenografts [8].